Community Paramedicine Community Paramedic CP model Innovative solution providing quality primary care and preventative services by employing a. Rf Global Game Cp' title='Rf Global Game Cp' />Stephen Hauser UCSF Profiles. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser S, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Infliximab for the treatment of CNS sarcoidosis A multi institutional series. Neurology. 2. 01. Oct 1. 3. PMID 2. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Bdingen HC, Henry RG, Hauser S, Chan JR. Clemastine fumarate as a remyelinating therapy for multiple sclerosis Re. Recent articles from AI and industry news from moreover. SOLO Packs are PERMANENTLY DISABLED. We encourage you to make friends ingame and eventually form a guild for which your guild leader will follow the Guild Pack. BUILD a randomised, controlled, double blind, crossover trial. Lancet. 2. 01. 7 Oct 1. PMID 2. 90. 29. 89. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree Hartman E, Katz Sand I, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. Sep 1. 1. PMID 2. Gelfand JM, Cree BAC, Hauser S. Ocrelizumab and Other CD2. B Cell Depleting Therapies in Multiple Sclerosis. Download The Scar Solution Ebook. Neurotherapeutics. Jul 1. 0. PMID 2. Hauser S, Van. Leeuwen J E. STAT editorial. VA can usher in the future of health care and research. Hauser SL, Bar Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L. Ocrelizumab versus Interferon Beta 1a in Relapsing Multiple Sclerosis. N Engl J Med. 2. 01. PMID 2. 80. 02. 67. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2. 01. PMID 2. 80. 02. 68. Bdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL. Onset of secondary progressive MS after long term rituximab therapy a case report. Ann Clin Transl Neurol. Jan 41 4. 6 5. PMID 2. Cree B, Gourraud PA, Oksenberg JR, Bevan C, Crabtree Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Bdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser S, et al. Long term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2. 01. Oct 8. 04 4. 99 5. PMID 2. 74. 64. 26. George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedstrm A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Sndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, DAlfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF. Multiple sclerosis risk loci and disease severity in 7,1. Neurol Genet. 2. 01. Aug 24 e. 87. PMID 2. PMCID PMC4. 97. 48. Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R, Caillier SJ, Santaniello A, Lize A, Himmelstein DS, Baranzini SE, Hollenbach J, Cree BA, Hauser S, Oksenberg JR, Henry RG, et al. Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. JAMA Neurol. 2. 01. Jul 0. 1 7. 37 7. PMID 2. 72. 44. 29. Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, DAlfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Grger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli Boneschi F, Mc. Cauley J, Montalban X, Muhlau M, Pelletier D, Pattany PM, Pericak Vance M, Rebeix I, Rocca M, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BM, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F, Hauser S, Oksenberg JR, Henry RG. Power estimation for non standardized multisite studies. Neuroimage. 2. 01. Jul 0. 1 1. 34 2. PMID 2. 70. 39. 70. Khankhanian P, Cozen W, Himmelstein DS, Madireddy L, Din L, van den Berg A, Matsushita T, Glaser SL, Mor JM, Smedby KE, Baranzini SE, Mack TM, Lize A, de Sanjos S, Gourraud PA, Nieters A, Hauser SL, Cocco P, Maynadi M, Foretov L, Staines A, Delahaye Sourdeix M, Li D, Bhatia S, Melbye M, Onel K, Jarrett R, Mc. Vuescan 8.3 32 Serial on this page. Kay JD, Oksenberg JR, Hjalgrim H. Meta analysis of genome wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. Int J Epidemiol. 2. Jun 4. 53 7. 28 4. PMID 2. 69. 71. 32. PMCID PMC5. 00. 59. Didonna A, Isobe N, Caillier SJ, Li KH, Burlingame AL, Hauser S, Baranzini SE, Patsopoulos NA, Oksenberg JR. A non synonymous single nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome. Hum Mol Genet. 2. Dec 1. 5 2. 42. PMID 2. PMCID PMC5. 00. 76. Available on 1. 21. Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TM, Booth D, Buck D, Celius EG, Cotsapas C, DAlfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Lar Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J, Kockum I, Leslie S, Lill CM, Martinelli Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Sndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak Vance MA, Spencer CC, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, Mc. Cauley JL, Sawcer S, Mc. Vean G. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 2. 01. Oct 4. 71. 0 1. PMID 2. PMCID PMC4. 87. 42. Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Bdingen HC, Waubant E, Goodin DS, Cree BA, Hauser SL, Henry RG. Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurol. 2. 01. Aug 7. 28 8. 97 9. PMID 2. 60. 53. 11. Khankhanian P, Matsushita T, Madireddy L, Lize A, Din L, Mor JM, Gourraud PA, Hauser SL, Baranzini SE, Oksenberg JR. Genetic contribution to multiple sclerosis risk among Ashkenazi Jews. BMC Med Genet. 2. Jul 2. 8 1. 6 5. PMID 2. PMCID PMC4. 55. 78. Tranah GJ, Santaniello A, Caillier SJ, DAlfonso S, Martinelli Boneschi F, Hauser SL, Oksenberg JR. Mitochondrial DNA sequence variation in multiple sclerosis. Neurology. 2. 01. Jul 2. 8 8. 54 3. PMID 2. 61. 36. 51. PMCID PMC4. 52. 08. Hauser SL. Advancing ethical neuroscience. Ann Neurol. 2. 01. May 7. 75 7. 35 7. PMID 2. 58. 20. 32. Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, Mor JM, Gourraud PA, Mc. Cauley JL, Beecham AH, Piccio L, Herbert J, Khan O, Cohen J, Stone L, Santaniello A, Cree BA, Onengut Gumuscu S, Rich SS, Hauser SL, Sawcer S, Oksenberg JR. An Immuno. Chip study of multiple sclerosis risk in African Americans. Brain. 2. 01. 5 Jun 1. Pt 6 1. 51. 8 3. PMID 2. PMCID PMC4. 55. 39.